MENINGOCOCCAL MENINGITIS B "BEXSERO" FACTS


Meningococcal Meningitis (Group B) "BEXSERO" is made by vaccine manufacturer Merck. This vaccine is intended for ages 10 years - 25 years of age. (2 doses is recommended) Other meningococcal vaccines are recommended to help protect against Serogroup A, C, W, and Y. Initial U.S approval: 2015


SYMPTOMS OF MENINGOCOCCAL MENINGITIS B:

Meningitis symptoms include sudden onset of fever, headache, and stiff neck. There are often other symptoms, such as Nausea, Vomiting, Photophobia (increased sensitivity to light), Altered mental status (confusion)


TRANSMISSION:

Meningococcal disease can spread from person to person through close contact (coughing or kissing) 


INGREDIENTS:

1. Aluminum Hydroxide - (ANTACID)

2. E.coli - (BACTERIUM found in the intestines of humans and animals)

3. Histidine - (AMINO ACID)

4. Sucrose - (CANE or BEET SUGAR)

5. Deoxycholate - (CHOLANOIC ACID)

6. Kanamycin - (ANTIBIOTIC)


YOU SHOULD NOT GET THIS VACCINATION IF:

1. If you have ever had a life-threatening allergic reaction after a previous dose of Serogroup B meningococcal vaccine, or if you have a severe allergy to any part of this vaccine, you should not get the vaccine.

2. Pregnant woman or breastfeeding mother

3. If you are moderately or severely ill, you should probably wait until you recover. 


CONTRAINDICATION:

1. Hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO


WARNING:

1. We only vaccinate for 5 of the 12 types: Men B and Men A, C, Y and W-135

2. Sufficient data is NOT available on the Safety and Effectiveness of BEXSERO and other Meningococcal Group B vaccines interchangeably to complete the vaccination series.

3. Appropriate observation and medical treatment should always be readily available in case of an anaphylactic event following the administration

4. Syncope (fainting) can occur in association with administration of BEXSERO.

5. The tip caps of the prefilled syringes contain natural rubber latex which may cause allergic reactions

6. BEXSERO MAY NOT protect all vaccine recipients. BEXSERO MAY NOT provide protection against all meningococcal Serogroup B strains

7. Some individuals with altered immunocompetence may have Reduced immune responses to BEXSERO.

8. It is NOT known whether BEXSERO is excreted in human milk.

9. Safety and Effectiveness of BEXSERO have NOT been established in children younger than 10 years

10. Safety and Effectiveness of BEXSERO have NOT been established in adults older than 65 years

11. BEXSERO has NOT been evaluated for Carcinogenic (CANCER) Mutagenic (DNA MUTATION) potential or Impairment of male fertility (INFERTILITY) 


DRUG INTERACTION:

1. Data is NOT available to establish the Safety/Immunogenicity of concomitant administration of BEXSERO with recommended adolescent vaccines